Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C27H29NO11 · xHCl
CAS Number:
Molecular Weight:
543.52 (free base basis)
UNSPSC Code:
12352200
MDL number:
Quality Segment
assay
≥98% (HPLC)
form
powder
potency
100 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic), protect from light
color
orange to red
solubility
water: 10 mg/mL
shipped in
ambient
storage temp.
10-30°C
InChI
1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10?,13?,15-,17?,22?,27-;/m0./s1
InChI key
MWWSFMDVAYGXBV-FGBJBKNOSA-N
General description
An anti-tumor antibiotic and a highly effective myotoxin that inhibits topoisomerase II (IC50 = 100 nM). Binds to nucleic acids, presumably by specific intercalation into the DNA double helix, inhibiting nucleic acid synthesis. Cytotoxicity seems to be due to its ability to intercalate with DNA, interact with plasma membranes, and take part in oxidation-reduction reactions. Induces apoptosis in rhabdomyosarcoma cell lines.
Antitumor antibiotic and a highly effective myotoxin that inhibits topoisomerase II (IC50 = 100 nM). Binds to nucleic acids, presumably by specific intercalation into the DNA double helix, thereby inhibiting nucleic acid synthesis. Induces apoptosis in rhabdomyosarcoma cell lines. Also available as a 10 mM solution in H2O (Cat. No. 504042).
Doxorubicin HCl, CAS 25316-40-9, is an antitumor antibiotic that inhibits topoisomerase II (IC₅₀ = 100 nM).
Biochem/physiol Actions
Primary Target
topoisomerase 2
topoisomerase 2
Product does not compete with ATP.
Preparation Note
Following reconstitution, refrigerate (4°C). Stock solutions are stable for up to 1 month at 4°C. Under acidic conditions doxorubicin is converted to a water-insoluble adriamycinone and a water soluble reducing sugar, daunosamine.
Other Notes
A′Hern, R.P., and Gore, M.E. 1995. J. Clin. Oncol. 13, 726.
Nooter, K., et al. 1995. Br. J. Cancer 71, 556.
Noviello, E., et al. 1994. Mutat. Res.311, 21.
Anderson, R.D., et al. 1993. Mutat. Res.294, 215.
Hershko, C., et al. 1993. J. Lab. Clin. Med.122, 245.
Jongmans, W., et al. 1993. Mutat. Res.294, 207.
O′Shaughnessy, J.A., and Cowan, K.H. 1993. J. Am. Med. Assoc.270, 2089.
Theyer, G., et al. 1993. J. Urol.150, 1544.
Tritton, T.R., and Yee, G. 1982. Science217, 248.
Nooter, K., et al. 1995. Br. J. Cancer 71, 556.
Noviello, E., et al. 1994. Mutat. Res.311, 21.
Anderson, R.D., et al. 1993. Mutat. Res.294, 215.
Hershko, C., et al. 1993. J. Lab. Clin. Med.122, 245.
Jongmans, W., et al. 1993. Mutat. Res.294, 207.
O′Shaughnessy, J.A., and Cowan, K.H. 1993. J. Am. Med. Assoc.270, 2089.
Theyer, G., et al. 1993. J. Urol.150, 1544.
Tritton, T.R., and Yee, G. 1982. Science217, 248.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Carcinogenic / Teratogenic (D)
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.

